Synlogic (SYBX)
Market Price (3/15/2026): $0 | Market Cap: $0Sector: Health Care | Industry: Biotechnology
Synlogic (SYBX)
Market Price (3/15/2026): $0Market Cap: $0Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -207% | Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -164% | Penny stockMkt Price is 0.6 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -63% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -48187% | |
| Megatrend and thematic driversMegatrends include Synthetic Biology & Live Biotherapeutics. Themes include Engineered Live Biotherapeutics, Microbiome-based Therapeutics, and Metabolic Disease Therapies (Novel Modalities). | Expensive valuation multiplesP/SPrice/Sales ratio is 939x | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -100% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 5438% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -50050%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -50050% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% | ||
| Key risksSYBX key risks include [1] a potential Nasdaq delisting over concerns it is a "public shell" and [2] significant financial instability following the discontinuation of its pivotal study for phenylketonuria (PKU). |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -207% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -63% |
| Megatrend and thematic driversMegatrends include Synthetic Biology & Live Biotherapeutics. Themes include Engineered Live Biotherapeutics, Microbiome-based Therapeutics, and Metabolic Disease Therapies (Novel Modalities). |
| Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -164% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -48187% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 939x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -100% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 5438% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -50050%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -50050% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% |
| Key risksSYBX key risks include [1] a potential Nasdaq delisting over concerns it is a "public shell" and [2] significant financial instability following the discontinuation of its pivotal study for phenylketonuria (PKU). |
Qualitative Assessment
AI Analysis | Feedback
Synlogic (SYBX) stock has lost about 60% since 11/30/2025 because of the following key factors:
1. Nasdaq Delisting Due to "Public Shell" Status Significantly Impaired Market Presence.
Synlogic received a notice from Nasdaq on November 21, 2025, stating that it was deemed a "public shell" and faced delisting. Following the withdrawal of its request for a hearing on January 16, 2026, trading of Synlogic's common stock was suspended from Nasdaq at the open of business on January 21, 2026. This move forced the stock to be quoted on the less liquid OTC Markets, which severely reduced its accessibility and appeal to a broad range of investors.
2. Persistent Weak Financial Performance Fueled Investor Concern.
The Nasdaq delisting was largely a consequence of Synlogic's ongoing weak financial performance, characterized by a lack of meaningful revenue, consistent losses, negative cash flow, and a diminishing equity and asset base. The company has remained unprofitable, experiencing an average annual revenue decline of 1.6%. For instance, in Q3 2024, Synlogic reported a loss of $0.01 per share, missing consensus estimates. This continuous financial instability created a fundamental lack of confidence in the company's long-term viability.
Show more
1. Nasdaq Delisting Due to "Public Shell" Status Significantly Impaired Market Presence.
Synlogic received a notice from Nasdaq on November 21, 2025, stating that it was deemed a "public shell" and faced delisting. Following the withdrawal of its request for a hearing on January 16, 2026, trading of Synlogic's common stock was suspended from Nasdaq at the open of business on January 21, 2026. This move forced the stock to be quoted on the less liquid OTC Markets, which severely reduced its accessibility and appeal to a broad range of investors.
2. Persistent Weak Financial Performance Fueled Investor Concern.
The Nasdaq delisting was largely a consequence of Synlogic's ongoing weak financial performance, characterized by a lack of meaningful revenue, consistent losses, negative cash flow, and a diminishing equity and asset base. The company has remained unprofitable, experiencing an average annual revenue decline of 1.6%. For instance, in Q3 2024, Synlogic reported a loss of $0.01 per share, missing consensus estimates. This continuous financial instability created a fundamental lack of confidence in the company's long-term viability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -58.2% change in SYBX stock from 11/30/2025 to 3/14/2026 was primarily driven by a -58.2% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.46 | 0.61 | -58.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 2,248.3 | 939.3 | -58.2% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -58.2% |
Market Drivers
11/30/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| SYBX | -58.2% | |
| Market (SPY) | -3.1% | 43.9% |
| Sector (XLV) | -5.0% | 4.9% |
Fundamental Drivers
The -57.9% change in SYBX stock from 8/31/2025 to 3/14/2026 was primarily driven by a -57.9% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.45 | 0.61 | -57.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 2,232.8 | 939.3 | -57.9% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -57.9% |
Market Drivers
8/31/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| SYBX | -57.9% | |
| Market (SPY) | 3.0% | 24.6% |
| Sector (XLV) | 9.5% | 6.1% |
Fundamental Drivers
The -55.5% change in SYBX stock from 2/28/2025 to 3/14/2026 was primarily driven by a -99.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.37 | 0.61 | -55.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 0 | -99.7% |
| P/S Multiple | 6.0 | 939.3 | 15476.4% |
| Shares Outstanding (Mil) | 12 | 12 | -0.8% |
| Cumulative Contribution | -55.5% |
Market Drivers
2/28/2025 to 3/14/2026| Return | Correlation | |
|---|---|---|
| SYBX | -55.5% | |
| Market (SPY) | 12.4% | 24.7% |
| Sector (XLV) | 1.9% | 10.9% |
Fundamental Drivers
The -94.2% change in SYBX stock from 2/28/2023 to 3/14/2026 was primarily driven by a -99.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3142026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.50 | 0.61 | -94.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | -99.5% |
| P/S Multiple | 30.3 | 939.3 | 3000.4% |
| Shares Outstanding (Mil) | 5 | 12 | -61.0% |
| Cumulative Contribution | -94.2% |
Market Drivers
2/28/2023 to 3/14/2026| Return | Correlation | |
|---|---|---|
| SYBX | -94.2% | |
| Market (SPY) | 73.4% | 15.3% |
| Sector (XLV) | 23.3% | 9.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SYBX Return | 12% | -69% | -66% | -64% | -20% | -46% | -98% |
| Peers Return | -21% | 19% | -7% | 12% | 51% | -14% | 27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| SYBX Win Rate | 42% | 33% | 42% | 17% | 42% | 33% | |
| Peers Win Rate | 43% | 50% | 42% | 52% | 53% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| SYBX Max Drawdown | 0% | -76% | -85% | -65% | -30% | -50% | |
| Peers Max Drawdown | -40% | -49% | -46% | -41% | -25% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DNA, BMRN, PTCT, RYTM, TVTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | SYBX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.7% | -25.4% |
| % Gain to Breakeven | 4228.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -56.5% | -33.9% |
| % Gain to Breakeven | 129.9% | 51.3% |
| Time to Breakeven | 308 days | 148 days |
| 2018 Correction | ||
| % Loss | -91.0% | -19.8% |
| % Gain to Breakeven | 1011.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to DNA, BMRN, PTCT, RYTM, TVTX
In The Past
Synlogic's stock fell -97.7% during the 2022 Inflation Shock from a high on 2/10/2021. A -97.7% loss requires a 4228.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Synlogic (SYBX)
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Synlogic (SYBX):
- Imagine a biotech company like **Moderna**, but instead of mRNA, they are engineering living bacteria to create medicines for various diseases.
- It's similar to **CRISPR Therapeutics**, but instead of gene-editing human cells, Synlogic engineers beneficial bacteria to act as therapeutic drugs.
- Think of it as a specialized **Ginkgo Bioworks**, focused exclusively on engineering therapeutic bacteria as drugs for human health.
AI Analysis | Feedback
```html- SYNB1618: An orally administered drug candidate in Phase II clinical trials for treating phenylketonuria.
- SYNB1934: An orally administered drug candidate in Phase II clinical trials for treating phenylketonuria.
- SYNB1353: An orally administered drug candidate for treating homocystinuria.
- SYNB8802: An orally administered drug candidate in Phase I clinical trial for treating enteric hyperoxaluria.
- SYNB1891: An intratumorally administered synthetic biotic medicine in Phase I clinical trial for treating solid tumors and lymphoma.
AI Analysis | Feedback
Synlogic (SYBX) is a clinical-stage biopharmaceutical company focused on the discovery and development of drug candidates. At this stage, the company does not sell finished products directly to individuals or other companies for commercial distribution. Instead, its primary source of funding and validation comes from collaboration agreements with other companies.
Based on the provided information, Synlogic's major collaborators, which function akin to key customers or partners in funding its development, are:
- F. Hoffmann-La Roche Ltd / Hoffmann-La Roche Inc. (commonly known as Roche). Roche is a major global pharmaceutical company. Its parent company is publicly traded on the SIX Swiss Exchange under the symbol ROG.
- Ginkgo Bioworks, Inc. (symbol: DNA)
AI Analysis | Feedback
- Ginkgo Bioworks, Inc. (DNA)
AI Analysis | Feedback
Synlogic is undergoing significant leadership changes as part of a major restructuring and workforce reduction, announced in February 2024. Here is a list of Synlogic's management team members: Aoife Brennan, M.B. Ch.B. President and Chief Executive Officer Dr. Brennan was appointed President and Chief Executive Officer of Synlogic in October 2018, having served as interim CEO since May 2018. She will be stepping down from her role and transitioning to a consulting position, also resigning from the Board of Directors, as part of the company's restructuring efforts announced in February 2024. She joined Synlogic in 2016 as Chief Medical Officer. Before Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, where she was involved in the global marketing approvals of ALPROLIX®, ELOCTATE®, and SPINRAZA®. Earlier in her career, she led clinical development at Tolerx, a startup biotech company focusing on immunotherapy for Type 1 diabetes. She has also served as a director and advisor for several public and private biotech companies, including Ra Pharmaceuticals, Inc. (which was acquired by UCB), and is currently on the boards of Cerevance, LLC, Xilio Therapeutics, and C-Path. Mary Beth Dooley Principal Financial Officer Mary Beth Dooley assumed the role of Principal Financial Officer at Synlogic, Inc. on March 18, 2024. She is also slated to become the Principal Executive Officer from January 1, 2025. No further detailed background information, including prior companies managed or involvement with private equity firms, is readily available in the provided search results. Antoine Awad Chief Operating Officer Antoine "Tony" Awad was promoted to Chief Operating Officer in July 2020, having joined Synlogic in December 2018 as Head of Technical Operations. With over 15 years of experience in the biotechnology and pharmaceutical industry, he has substantial expertise in the development and manufacturing of novel therapeutics from pre-IND studies through global commercialization. Prior to Synlogic, Mr. Awad held positions as Senior Vice President of CMC and Operations at Abpro Therapeutics and L.E.A.F. Pharmaceuticals. He also held roles of increasing responsibility over a decade at Merrimack Pharmaceuticals, where he led CMC development, manufacturing, and approval of ONIVYDE® for advanced pancreatic cancer, later transitioning to Ipsen Bioscience for its commercial manufacturing integration. His experience also includes broad involvement in partnerships, collaborations, and mergers and acquisitions with companies such as Sanofi, Baxalta/Shire plc, Actavis Pharma/Teva Pharmaceutical Industries, and Ipsen Bioscience. David L. Hava, Ph.D. Chief Scientific Officer Dr. Hava was appointed Chief Scientific Officer of Synlogic in September 2020 and became Head of Research and Development effective January 1, 2023. He brings over 14 years of experience in the pharmaceutical industry, leading platform and drug development programs. Before joining Synlogic, he served as Chief Scientific Officer at Metera Pharmaceuticals and Pulmatrix Inc., where he directed research, development, and clinical teams focused on respiratory therapies and advanced multiple programs into Phase 2 clinical development. Dr. Hava was also an Entrepreneur-in-Residence at Mass General Brigham Ventures and a founding CEO of a stealth startup. He has co-authored numerous manuscripts and abstracts in infectious disease, immunology, and chronic lung diseases.AI Analysis | Feedback
Key Risks for Synlogic (SYBX)
Clinical Trial Failure and Regulatory Approval Risk: Synlogic is a clinical-stage biopharmaceutical company with several drug candidates, including SYNB1618, SYNB1934, SYNB1353, SYNB8802, and SYNB1891, currently in Phase I and Phase II clinical trials. The success of the company's business model is critically dependent on the successful outcome of these clinical trials and the subsequent ability to obtain regulatory approvals for its synthetic biotic medicines. Failure at any stage of clinical development, or inability to secure necessary regulatory clearances, would significantly jeopardize the company's prospects and future revenue generation.
Dependence on Successful Research and Development of Novel Synthetic Biotic Medicines: The company's core strategy revolves around the "discovery and development of synthetic biotic medicines" for metabolic and immunological diseases. This involves complex and inherently uncertain scientific and technical challenges related to the design, development, and manufacturing of these novel therapeutic candidates. The inability to successfully advance new synthetic biotic medicines through its research and development pipeline, or if the underlying technology proves ineffective or unfeasible, poses a substantial risk to the company's long-term viability and growth.
Funding and Capital Requirements: As a clinical-stage biopharmaceutical company without any approved products generating revenue, Synlogic relies heavily on external funding to finance its significant research and development expenditures and ongoing clinical trials, which are capital-intensive. The ability to raise additional capital when needed, and on commercially reasonable terms, is crucial. A shortfall in funding could lead to delays or termination of its drug development programs.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Market Sizes for Synlogic's Main Products
- Phenylketonuria (PKU) (SYNB1618 and SYNB1934): The global phenylketonuria treatment market was valued at approximately USD 700 million in 2023 and is anticipated to grow significantly through 2034. Other estimates place the global market size at USD 1.17 billion in 2023, projected to reach USD 2.02 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.3% during the forecast period (2024–2032). Another report valued the global market at USD 518.7 million in 2024, projected to reach USD 851.0 million by 2030, with a CAGR of 9.4% from 2025 to 2030. The U.S. market alone accounted for approximately 60% of the total market size across the 7 major markets (7MM) in 2023, with 18,000 diagnosed prevalent cases of PKU in the U.S. North America is noted as holding a dominant position in the global PKU market.
- Homocystinuria (SYNB1353): The global homocystinuria market is expected to reach US$ 94.50 million by 2034, growing from US$ 66.25 million in 2025, at a CAGR of 4.03% during 2026–2034. Another report estimates the global market to expand from $66.3 million in 2024 to $95.3 million by 2034, with a CAGR of approximately 4.3%. Historically, the market was expected to reach US$ 73.96 million by 2028 from US$ 56.58 million in 2021, with a CAGR of 3.9% during 2021–2028. In the United States, Homocystinuria is classified as a rare disease, generally affecting fewer than 200,000 individuals. The United States holds the largest patient pool and represents the largest market for homocystinuria treatment among the 7MM.
- Enteric Hyperoxaluria (SYNB8802): There are an estimated 250,000 patients with enteric hyperoxaluria in the United States. Enteric hyperoxaluria is an acquired metabolic disorder that currently has no approved treatment options. The broader global hyperoxaluria drug market (including primary and secondary forms) was valued at USD 19.43 million in 2024 and is expected to reach USD 32.40 million by 2032, with a CAGR of 6.6%. The global primary hyperoxaluria treatment market reached US$ 168.96 million in 2023 and is expected to reach US$ 365.49 million by 2031, growing at a CAGR of 9.8% during the forecast period 2024-2031. The U.S. primary hyperoxaluria market alone was valued at approximately $170 million in 2024, with an expected growth rate of 8.4% from 2025–2032.
-
Solid Tumors and Lymphoma (SYNB1891):
- Solid Tumors: The global solid tumors market reached a value of US$ 170.3 billion in 2023 and is expected to reach US$ 375.4 billion by 2034, exhibiting a CAGR of 7.45% during 2024-2034. Another estimate for the global solid tumors market size was USD 362.21 billion in 2024, projected to reach USD 1557.42 billion by 2032, with a CAGR of 20.00% during 2025 to 2032. The top 7 markets (US, EU4, UK, and Japan) for solid tumors reached USD 183.0 billion in 2024 and are expected to reach USD 406.4 billion by 2035. North America consistently dominates the solid tumors market.
- Lymphoma: The global lymphoma treatment market is projected to grow from USD 10.85 billion in 2026 to USD 16.17 billion by 2031. Another source indicates the global lymphoma therapeutics market size was calculated at USD 7.85 billion in 2024, growing to USD 8.52 billion in 2025, and projected to reach around USD 17.75 billion by 2034, at a CAGR of 8.5% from 2025 to 2034. North America is reported to have dominated the lymphoma treatment market, with the U.S. specifically holding a large revenue share.
AI Analysis | Feedback
For Synlogic (NASDAQ: SYBX), the expected drivers of future revenue growth over the next 2-3 years are primarily tied to strategic corporate decisions and the potential advancement of its remaining early-stage pipeline, following the discontinuation of its lead phenylketonuria (PKU) program.
-
Monetization through Strategic Alternatives: Synlogic is actively exploring strategic alternatives, including potential mergers, acquisitions, or other business combinations, to maximize shareholder value. A successful outcome from this process could generate revenue through the sale of the company, its assets, or intellectual property.
-
Advancement and Potential Partnering of SYNB1353 for Homocystinuria (HCU): While still in early clinical development (Phase 1 proof of mechanism achieved), the successful progression of SYNB1353, which has received FDA Fast Track and Orphan Drug Designations, could attract new partnerships or trigger milestone payments from any future collaborations.
-
Advancement and Potential Partnering of SYNB8802 for Enteric Hyperoxaluria: SYNB8802 has demonstrated proof of mechanism. Continued positive clinical development of this candidate could lead to licensing deals or collaboration agreements with potential milestone payments, contributing to future revenue.
-
Entry into New Research and Development Collaborations: Synlogic has historically generated revenue from research collaborations, such as its prior agreement with Roche. Forming new strategic partnerships with other pharmaceutical or biotechnology companies could provide upfront payments, research funding, and potential future milestone payments based on the achievement of development or commercial goals.
AI Analysis | Feedback
Share Issuance
- In September 2021, Synlogic announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at $3.00 per share, anticipating gross proceeds of $45.0 million. The company also granted the underwriters an option to purchase up to 2,250,000 additional shares.
- Synlogic completed an underwritten public offering in October 2023, generating approximately $21.0 million in gross proceeds. This offering included 7,394,363 shares of common stock (or pre-funded warrants) and accompanying common warrants, with a combined effective offering price of $2.84 per unit.
- In September 2023, Synlogic executed a 1-for-15 reverse stock split to meet Nasdaq's minimum bid price requirement. This action reduced the number of outstanding common shares from about 69.0 million to approximately 4.6 million.
Inbound Investments
- Synlogic earned a $2.5 million milestone payment in November 2023 from its collaboration agreement with Roche. This payment was for achieving a research milestone in the pre-clinical development of a Synthetic Biotic for inflammatory bowel disease.
- The company's annual revenue significantly decreased to approximately $0.01 million in 2024 from $3.4 million in 2023, primarily due to the conclusion of the Roche collaboration.
Capital Expenditures
- Synlogic's research and development expenses saw a substantial reduction, decreasing to $9.2 million in 2024 from $44.0 million in 2023. This reduction was primarily due to the discontinuation of the Synpheny-3 trial and other pipeline projects.
- The company reported very low research and development expenses of only $16,000 for the nine months ended in 2025, reflecting a significant scale-back of operations.
Trade Ideas
Select ideas related to SYBX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 43.16 |
| Mkt Cap | 3.9 |
| Rev LTM | 340 |
| Op Inc LTM | -33 |
| FCF LTM | -12 |
| FCF 3Y Avg | -85 |
| CFO LTM | 17 |
| CFO 3Y Avg | -77 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 29.3% |
| Rev Chg 3Y Avg | 45.0% |
| Rev Chg Q | 17.0% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | -57.0% |
| Op Mgn 3Y Avg | -158.9% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | -26.6% |
| CFO/Rev 3Y Avg | -101.9% |
| FCF/Rev LTM | -32.6% |
| FCF/Rev 3Y Avg | -122.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.9 |
| P/S | 4.3 |
| P/EBIT | -0.9 |
| P/E | -1.8 |
| P/CFO | 2.8 |
| Total Yield | -2.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.8% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.9% |
| 3M Rtn | -21.6% |
| 6M Rtn | -1.8% |
| 12M Rtn | 7.9% |
| 3Y Rtn | -1.3% |
| 1M Excs Rtn | -6.2% |
| 3M Excs Rtn | -16.3% |
| 6M Excs Rtn | -5.9% |
| 12M Excs Rtn | -9.7% |
| 3Y Excs Rtn | -72.9% |
Price Behavior
Price Behavior
| Market Price | $0.61 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/01/2015 | |
| Distance from 52W High | -66.7% | |
| 50 Days | 200 Days | |
| DMA Price | $1.15 | $1.35 |
| DMA Trend | up | down |
| Distance from DMA | -47.0% | -54.9% |
| 3M | 1YR | |
| Volatility | 155.1% | 80.5% |
| Downside Capture | 677.66 | 171.52 |
| Upside Capture | 186.31 | 55.24 |
| Correlation (SPY) | 32.9% | 23.6% |
SYBX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.00 | 4.68 | 3.73 | 1.75 | 0.94 | 0.89 |
| Up Beta | 0.00 | -0.73 | 1.94 | 0.21 | 0.64 | 0.70 |
| Down Beta | � | 13.69 | 10.80 | 5.56 | 1.47 | 1.24 |
| Up Capture | 1% | 2% | -110% | -47% | 30% | 3% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 1 | 8 | 18 | 48 | 106 | 325 |
| Down Capture | -0% | 436% | 342% | 172% | 125% | 109% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 0 | 8 | 16 | 47 | 102 | 357 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYBX | |
|---|---|---|---|---|
| SYBX | -56.2% | 80.7% | -0.75 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 10.9% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 24.4% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | -14.3% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | 3.2% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 17.7% |
| Bitcoin (BTCUSD) | -15.3% | 44.2% | -0.25 | 28.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYBX | |
|---|---|---|---|---|
| SYBX | -59.1% | 84.8% | -0.67 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 10.9% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 16.9% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | 1.6% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 3.0% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 16.3% |
| Bitcoin (BTCUSD) | 6.3% | 56.7% | 0.33 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SYBX | |
|---|---|---|---|---|
| SYBX | -48.6% | 83.9% | -0.41 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 19.4% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 23.7% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | 2.9% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 8.3% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 19.7% |
| Bitcoin (BTCUSD) | 67.4% | 66.8% | 1.07 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2024 | -3.4% | -6.8% | 4.1% |
| 8/8/2024 | -4.3% | -14.0% | -11.6% |
| 5/14/2024 | -2.8% | -10.0% | -11.1% |
| 2/12/2024 | 1.2% | 7.0% | 8.1% |
| 11/9/2023 | -15.0% | -1.4% | 34.7% |
| 8/10/2023 | 1.5% | 7.3% | -6.1% |
| 3/29/2023 | 2.9% | -12.5% | -14.9% |
| 11/10/2022 | -6.9% | 3.5% | 1.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 9 | 9 |
| # Negative | 10 | 7 | 7 |
| Median Positive | 4.7% | 7.3% | 8.2% |
| Median Negative | -4.5% | -8.9% | -7.5% |
| Max Positive | 14.4% | 43.9% | 34.7% |
| Max Negative | -15.0% | -14.0% | -14.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/19/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/17/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dooley, Mary Beth | See Remarks below | Direct | Sell | 10312025 | 1.81 | 157 | 284 | 23,067 | Form |
| 2 | Dooley, Mary Beth | See Remarks below | Direct | Sell | 4032025 | 1.20 | 144 | 173 | 15,481 | Form |
| 3 | Dooley, Mary Beth | See Remarks below | Direct | Sell | 2042025 | 1.33 | 2,107 | 2,802 | 17,350 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.